Navigating the complexities of pharmaceutical manufacturing can be challenging, especially when it comes to ensuring compliance with regulatory standards. One of the most critical aspects is understanding the Qualified Person requirements, which are essential for maintaining product quality and patient safety because they establish legal accountability for batch certification and release. This article delves into the specific responsibilities and legal obligations of Qualified Persons (QPs), providing clarity on their pivotal role in the industry.
How can qualified person requirements support compliant qp release strategies?
Efficient QP release hinges on seamlessly integrating Qualified Person requirements into your Pharmaceutical Quality System (PQS). In the EU, this includes compliance with Annex 16 of EudraLex Vol. 4, which specifies the QP’s role in certifying each batch prior to market release. At Billev Pharma East, we specialize in providing tailored GMP support—covering everything from documentation review and deviation management to batch certification for various product types (sterile medicinal products, biologicals, ATMPs, small molecules) across all stages of development, from clinical to commercial.
Incorporating these Qualified Person requirements ensures that your data—batch records, analytical results, audit trails, and Product Quality Reviews—is comprehensive, audit-ready and compliant with the marketing authorisation. In our own experience, companies that align documentation review procedures early in the manufacturing cycle reduce QP release delays substantially.
What makes qualified person requirements so crucial for global companies?
For multinational pharmaceutical companies, navigating diverse regulatory environments is a complex and high-stakes challenge as responsibilities and enforcement frameworks differ significantly between regions. That’s why Qualified Person requirements are so vital, providing a clear framework that ensures legal accountability and product quality.
At Billev Pharma East, we offer integrated consulting services encompassing product development, regulatory affairs, pharmacovigilance, quality system management, and regulatory informatics to help you meet these standards globally. With our expertise in both EU and international regulations, we ensure your processes are robust and compliant—across markets and across the product lifecycle.
How do qualified person requirements differ between the EU and the US regulatory systems?
In the EU, the QP holds a personal legal responsibility: under Directive 2001/83/EC, Article 51, every batch released to the EU market must be certified by a QP, with the individual personally responsible for compliance with GMP and the marketing authorization. This includes rigorous oversight of supply chains, audits, validation, and stability data.
This contrasts with many non-EU jurisdictions, where accountability lies with a quality unit or corporate entity rather than an individual. The most striking difference is the absence of a QP role in the US regulatory framework. The FDA (21 CFR Parts 210–211) requires that the Quality Unit approve or reject all drug products, but the law does not impose personal legal liability on an individual comparable to the EU QP.
For any US company exporting to the EU, however, EU-based QP certification is mandatory. This often requires partnering with an EU‑based QP—or employing one. From our perspective, US firms sometimes underestimate the impact of this requirement until late in the supply chain, creating avoidable delays in batch certification for import.
The impact of Qualified Person requirements on manufacturing timelines
Integrating Qualified Person requirements adds a defined stage to manufacturing workflows and batch release process. According to EU regulation, the QP must confirm that complete qualitative and quantitative analyses of all active substances have been conducted, and that the batch complies in full with the marketing authorization.
For companies managing cross-border supply, this means that, unlike in the US, every batch destined for the EU may require multiple additional days of analytical and documentation review to comply with Qualified Person requirements—a time cost that must be factored into global release strategies.
Why are qualified person requirements considered stricter in some regions?
Qualified Person requirements in the EU involve multidimensional accountability—legal, ethical, and professional. The QP must ensure that the entire supply chain, from starting materials to final product, complies with GMP and marketing authorisations, and that audits, documentation, deviations, stability, and changes are fully addressed before final certification.
In other jurisdictions, such as some PIC/S member states, similar functions exist (e.g. a “Responsible Person”), but the regulatory frameworks typically stop short of imposing the same degree of personal legal accountability. This makes the EU’s requirements unique in their rigor.
How do qualified person requirements influence supply chain oversight?
The QP’s role extends beyond batch release: they must oversee supplier qualification, risk assessment, product traceability, change management and audit integrity.
Specifically, the QP must confirm that active substances and excipients comply with GMP and marketing authorisation files, supplier sites are audited, change controls are reviewed, and quality agreements are in place—especially in outsourced or multi-site manufacturing contexts.
Quantifying the role of Qualified Person requirements in mitigating drug shortages
Empirical models indicate that implementing more resilient supply chain configurations, underpinned by qualified person requirements, can dramatically reduce drug shortages. A study modeling generic injectable oncology supply logistics revealed that a back-up supplier combined with rigorous QP-led oversight reduced expected shortages from the baseline 10 % to just 4 %—an improvement attributable to strengthened supply chain governance. This underscores not just the regulatory necessity but also the operational value of embedding qualified person requirements in global manufacturing networks.
Which qualified person requirements changed most post-Brexit?
While the EU and UK still share the foundational frameworks (e.g. Annex 16), the UK now operates under its own legal regime. The UK QP remains a personally accountable position, authorised under UK‑specific legislation and following the UK Code of Practice, which includes requirements for indemnity and individual qualification aligned with MHRA expectations.
These changes reinforce Qualified Person requirements for companies exporting to or operating within the UK—requiring explicit consideration of UK regulations alongside EU norms.
How do regional variations in qualified person requirements impact global drug availability?
Variations in QP eligibility, responsibility, and batch certification procedures directly affect global supply chains. For instance, batches entering the EU or UK must be certified by a licensed and locally registered QP—an operational requirement absent in many other jurisdictions.
This compels global manufacturers to build modular compliance systems capable of meeting the strictest qualified person requirements across regions—ensuring uninterrupted supply, regulatory readiness, and consistent quality worldwide.
Frequently asked questions
What are the duties of qualified person?
The duties of the QP include personally certifying that each medicinal product batch has been manufactured and tested in compliance with Good Manufacturing Practice, the marketing authorisation, and national legislation, thereby fulfilling the stringent Qualified Person requirements before release. Additionally, the QP is responsible for oversight of the entire supply chain, including supplier qualification, audits, validation, and documentation integrity, ensuring product quality and patient safety.
What is the role of a qualified person?
The Qualified Person requirements are explicitly defined in Article 51 of Directive 2001/83/EC, which mandates that a qualified person must certify that each batch of medicinal products has been manufactured and checked in compliance with the laws in force in the Member State and in accordance with the requirements of the marketing authorisation.
These requirements encompass ensuring that manufacturing and testing processes adhere to Good Manufacturing Practice (GMP) standards, reviewing all relevant documentation, and certifying that the product is safe and effective for patient use.
Additionally, the qualified person must oversee the entire supply chain, including supplier qualification, audits, and documentation integrity, to ensure compliance with the Qualified Person requirements and maintain product quality and patient safety.
Read also:
- What steps must a QP follow to ensure a proper QP release and uphold the GMP certificate?
- How does an outsourced QP service ensure compliance and risk mitigation?
- What key services are typically offered by GMP consulting services?
Sources: 1– EudraLex,Volume 4, Annex 16: Certification by a Qualified Person and Batch Release, 2 – Pharmaceutical Technology – PharmTech. (2010, October 2). The Role of the Qualified Person in European Pharmaceutical Regulations, 3 – Industrial Pharmacist. (2023, August 19). The Role and Duties of the EU Qualified Person (QP) | Part I, 4 – Tucker, E. L., & Daskin, M. S. (2021). Pharmaceutical supply chain reliability and effects on drug shortages, 5 – Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.